Key Takeaways
-
Epitech Group and Horus Pharma have signed a global licensing agreement granting Horus Pharma exclusive rights to adelmidrol for ophthalmic and periocular dermatologic applications
-
The partnership combines Epitech Group's ALIAmide research with Horus Pharma's ophthalmic development and commercialization expertise.
Epitech Group, an Italian biopharmaceutical company specializing in neuroinflammation, and Horus Pharma, a French ophthalmic pharmaceutical company, have entered into a global licensing agreement to develop and commercialize adelmidrol for ophthalmic and periocular dermatologic applications.
Financial terms of the deal were not disclosed.
Under the agreement, Horus Pharma receives exclusive global rights to develop and market adelmidrol, a molecule belonging to the ALIAmide family developed by Epitech Group, for human ophthalmology and periocular dermatology.
The collaboration aims to investigate the molecule's potential in addressing unmet needs in ocular health, particularly as aging populations, chronic diseases, and increasingly complex ocular surface disorders create demand for additional treatment options.
Epitech Group brings more than 30 years of research into ALIAmides and their involvement in physiological regulatory mechanisms. Its work builds on research by Rita Levi-Montalcini, the 1986 Nobel Prize in Physiology or Medicine recipient, who identified the ALIA mechanism.
Horus Pharma contributes more than 20 years of ophthalmology experience, along with research and development capabilities and an established international presence. The company will oversee the development and commercialization of ophthalmic products containing adelmidrol.